INmune Bio/$INMB
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Ticker
$INMB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
18
ISIN
US45782T1051
Website
INmune Bio Metrics
BasicAdvanced
$168M
-
-$1.94
1.64
-
Price and volume
Market cap
$168M
Beta
1.64
52-week high
$10.50
52-week low
$4.32
Average daily volume
486K
Financial strength
Current ratio
2.644
Quick ratio
2.618
Long term debt to equity
0.677
Total debt to equity
1.169
Interest coverage (TTM)
-96.12%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-81,592.00%
Operating margin (TTM)
-83,046.00%
Management effectiveness
Return on assets (TTM)
-61.33%
Return on equity (TTM)
-139.01%
Valuation
Price to revenue (TTM)
3,050.99
Price to book
5.59
Price to tangible book (TTM)
12.62
Price to free cash flow (TTM)
-4.662
Free cash flow yield (TTM)
-21.45%
Free cash flow per share (TTM)
-155.30%
Growth
Revenue change (TTM)
-61.83%
Earnings per share change (TTM)
1.07%
3-year revenue growth (CAGR)
-47.22%
3-year earnings per share growth (CAGR)
0.28%
What the Analysts think about INmune Bio
Analyst ratings (Buy, Hold, Sell) for INmune Bio stock.
INmune Bio Financial Performance
Revenues and expenses
INmune Bio Earnings Performance
Company profitability
INmune Bio News
AllArticlesVideos
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
GlobeNewsWire·2 months ago
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
GlobeNewsWire·2 months ago
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for INmune Bio stock?
INmune Bio (INMB) has a market cap of $168M as of June 21, 2025.
What is the P/E ratio for INmune Bio stock?
The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of June 21, 2025.
Does INmune Bio stock pay dividends?
No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next INmune Bio dividend payment date?
INmune Bio (INMB) stock does not pay dividends to its shareholders.
What is the beta indicator for INmune Bio?
INmune Bio (INMB) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
